Product Code: ETC8838569 | Publication Date: Sep 2024 | Updated Date: Jun 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
This market is witnessing steady growth as insulin pump therapy becomes more accessible to diabetic patients. Continuous subcutaneous insulin infusion (CSII) provides better glycemic control and lifestyle flexibility. Support from endocrinologists and diabetes educators is driving adoption, along with a rise in private insurance reimbursements and newer, compact pump designs.
The continuous subcutaneous insulin infusion market is growing alongside the increasing prevalence of diabetes and demand for more precise glycemic control methods. Insulin pumps offer better flexibility and quality of life for patients. Support from healthcare providers, insurance coverage, and advancements in pump technology contribute to wider adoption. Integration with CGM systems further enhances market appeal.
This market encounters challenges stemming from the high price of insulin pumps and consumables, which restricts accessibility to a limited segment of diabetic patients. Regulatory approval processes for new devices can be lengthy, delaying introduction. There is also limited healthcare professional training on pump therapy, affecting prescription rates. Additionally, patient adherence to device use protocols and consistent monitoring remains a hurdle.
The rising prevalence of diabetes in the Philippines drives strong growth prospects for the Continuous Subcutaneous Insulin Infusion (CSII) Market. Investment opportunities exist in importing, distributing, and locally assembling advanced insulin pump technologies. Collaborations with healthcare providers and insurance companies can promote wider adoption of CSII devices, enhancing diabetes management. Furthermore, integrating these devices with digital health platforms offers avenues for innovation and improved patient adherence.
Continuous Subcutaneous Insulin Infusion (CSII) systems, commonly known as insulin pumps, are regulated by the FDA Philippines to ensure safety and efficacy. The DOH acknowledges the role of CSII in managing Type 1 diabetes and is working towards integrating these systems into public healthcare services. While currently not covered by PhilHealth, there is advocacy for their inclusion in insurance packages to improve diabetes management outcomes. The government is also supporting training programs for healthcare providers to effectively utilize CSII technology.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Continuous Subcutaneous Insulin Infusion Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Continuous Subcutaneous Insulin Infusion Market - Industry Life Cycle |
3.4 Philippines Continuous Subcutaneous Insulin Infusion Market - Porter's Five Forces |
3.5 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume Share, By End Use, 2021 & 2031F |
3.7 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
4 Philippines Continuous Subcutaneous Insulin Infusion Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Continuous Subcutaneous Insulin Infusion Market Trends |
6 Philippines Continuous Subcutaneous Insulin Infusion Market, By Types |
6.1 Philippines Continuous Subcutaneous Insulin Infusion Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Tethered, 2021- 2031F |
6.1.4 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Patch, 2021- 2031F |
6.2 Philippines Continuous Subcutaneous Insulin Infusion Market, By End Use |
6.2.1 Overview and Analysis |
6.2.2 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Homecare, 2021- 2031F |
6.2.4 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Laboratories, 2021- 2031F |
6.3 Philippines Continuous Subcutaneous Insulin Infusion Market, By Patient Type |
6.3.1 Overview and Analysis |
6.3.2 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Type 1 diabetes, 2021- 2031F |
6.3.3 Philippines Continuous Subcutaneous Insulin Infusion Market Revenues & Volume, By Type 2 diabetes, 2021- 2031F |
7 Philippines Continuous Subcutaneous Insulin Infusion Market Import-Export Trade Statistics |
7.1 Philippines Continuous Subcutaneous Insulin Infusion Market Export to Major Countries |
7.2 Philippines Continuous Subcutaneous Insulin Infusion Market Imports from Major Countries |
8 Philippines Continuous Subcutaneous Insulin Infusion Market Key Performance Indicators |
9 Philippines Continuous Subcutaneous Insulin Infusion Market - Opportunity Assessment |
9.1 Philippines Continuous Subcutaneous Insulin Infusion Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Philippines Continuous Subcutaneous Insulin Infusion Market Opportunity Assessment, By End Use, 2021 & 2031F |
9.3 Philippines Continuous Subcutaneous Insulin Infusion Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
10 Philippines Continuous Subcutaneous Insulin Infusion Market - Competitive Landscape |
10.1 Philippines Continuous Subcutaneous Insulin Infusion Market Revenue Share, By Companies, 2024 |
10.2 Philippines Continuous Subcutaneous Insulin Infusion Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |